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Abstract: 
There have been numerous studies reporting lower mortality rates in obese patients with 
various cardiovascular disorders than in non-obese patients, a phenomenon known as the 
" obesity paradox". Limited data exist regarding the effect of obesity on prognosis in 
patients with pulmonary arterial hypertension (PAH). We used the 2003-2011 National 
Inpatient Sample databases to identify all patient hospitalizations aged ≥18 years with a 
primary diagnosis of PAH. Patients with a diagnosis of obesity were identified using 
elixhauser comorbidity measure provided in NIS database, based on International 
Classification of Diseases, 9th Revision, Clinical Modification codes and the diagnosis 
related groups. Multivariable logistic regression was used to compare in-hospital 
mortality between obese and non-obese PAH patients. Of the 18, 450 patients with a 
primary diagnosis of PAH, 14.7% were obese. Obese patients with PAH were younger, 
more often female, and more often black when compared with non-obese white patients. 
After risk adjustment for demographics, hospital characteristics and baseline 
comorbidities, obese PAH patients had lower observed in-hospital mortality compared 
with non-obese PAH patients (3.5% versus 8.1%; adjusted odds ratio 0.66, 95% CI 0.51 
to 0.85, p=0.001). In conclusion, from a 9 year nationwide cohort of PAH patients, we 
observed significantly lower risk-adjusted in-hospital mortality in obese PAH patients 
compared to non-obese PAH patients. 
 
Keywords: Obesity, Pulmonary arterial hypertension, mortality, NIS, hospital 
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While obesity is an important independent cardiovascular (CV) risk factor, data exists 
supporting better survival outcomes in multiple clinical conditions, including coronary 
heart disease, heart failure, hypertension and chronic obstructive pulmonary disease. 1-6 
This epidemiological observation has been termed the “ obesity paradox”.  Pulmonary 
arterial hypertension (PAH), the result of pathophysiological changes in pulmonary 
vasculature leading to abnormally high pulmonary artery pressures, is an important CV 
condition leading to poor outcomes including right sided heart failure and death. Little is 
known about the effect of obesity on prognosis in PAH patients, and the need for studies 
examining the role of obesity in pulmonary vascular diseases has been emphasized 
previously.7-10 Hence, we analyzed the association of obesity with mortality in the 
Nationwide Inpatient Sample (NIS) databases from 2003 to 2011. 
Methods  
 We used Nationwide Inpatient Sample (NIS) of the Healthcare Cost and 
Utilization Project, the largest publicly available all-payer inpatient care database in the 
United States with discharge-level data available for approximately 8 million hospital 
stays each year and is designed to approximate a 20% stratified sample of United States 
hospitals.11 The first diagnosis is referred to as the “principal diagnosis” and is considered 
the primary reason for admission to the hospital. The NIS also provides ≤25 secondary 
diagnoses during that hospitalization and also carries information on patient 
demographics, hospitalization characteristics, insurance status, comorbidities, 
hospitalization outcome, and length of stay and cost of hospitalization. The internal and 
external validity of the NIS database are maintained through annual data quality 
assessments and comparison with other databases such as National Hospital Discharge 
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Survey and MedPar statistics. These reports are published on the NIS website: 
http://www.hcupus.ahrq.gov/db/nation/nis/nisrelatedreports.jsp. 
 All hospitalizations with the principal diagnosis of PAH in patients with age > 18 
years were identified using the International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9- CM) codes 416.0, as used previously.12 Obese patients 
were identified using the Agency for Healthcare Research and Quality -defined co-
morbidity measure, CM_Obese.11 Agency for Healthcare Research and Quality co-
morbidities that are provided in NIS were originally described by Elixhauser et al.13 using 
ICD-9-CM diagnoses and the diagnosis-related group in effect on the discharge/ death 
date.11 The definition of obesity includes the following ICD-9-CM codes: 278.0, 278.00, 
278.01, 278.03, 649.10-649.14, 793.91, V85.30-V85.39, V85.41-V85.45, and V85.54 and 
excludes the following diagnosis related group: 288, 296-298, 619-621, and 640-641.11 
Patient-level characteristics included: age, sex, race, primary payer status, weekday vs. 
weekend admission, all Elixhauser comorbidities11,13 provided as part of database (except 
obesity and pulmonary circulation disorders) - acquired immune deficiency syndrome, 
alcohol abuse, deficiency anemia, rheumatoid arthritis/collagen vascular diseases, chronic 
blood loss anemia, congestive heart failure, chronic renal failure, coagulopathy, 
depression, diabetes [uncomplicated], diabetes [with chronic complications], drug abuse, 
hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte disorders, 
metastatic cancer, other neurologic disorders, paralysis, peripheral vascular disease, 
psychosis, solid tumor without metastasis, valvular heart disease, and weight loss and 
other relevant CV comorbidities [smoking, dyslipidemia, previous myocardial infarction, 
obstructive sleep apnea and atrial fibrillation]. Hospital-level characteristics included the 
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following: location (urban or rural), bed size (small, medium, or large), region 
(Northeast, Midwest, South, or West), and teaching status. The principal outcome 
measure was in-hospital mortality. In addition to all variables listed in Table 1, obesity 
was used as an independent variable in a multivariable regression model to examine 
predictors of in-hospital mortality, labeled as “died” in the NIS. 
 All analyses were weighted using NIS provided weights to create national 
estimates. Categorical variables are expressed as percentages and continuous variables as 
mean ± standard deviation or median (25th, 75th percentile) as applicable. We initially 
compared the baseline patient and hospital characteristics between the 2 groups (non-
obese and obese). The Pearson chi -square test was used for categorical variables and the 
Student’s t-test or Mann Whitney U test for continuous variables. Multivariate 
unconditional logistic regression was then used to compare in-hospital mortality between 
patients with obesity and those without obesity, where we adjusted for patient 
demographics, hospital characteristics, all clinically comorbidities and hospital 
characteristics as mentioned above. Adjusted odds ratios and 95% confidence intervals 
were used to report the results of logistic regression. Statistical analysis was performed 
using IBM SPSS Statistics 23.0 (Armonk, New York, IBM corp.). A two-sided p-value of 
< 0.05 was considered significant. 
Results 
 18,450 hospitalized patients with a primary diagnosis of PAH at discharge or at 
death were identified. Table 1 describes the patient demographics, hospital characteristics 
and clinical comorbidities in the overall cohort and subgroups based on obesity diagnosis. 
In the overall cohort of PAH patients, obesity was associated with lower in-hospital 
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mortality (3.5% vs. 8.1%; unadjusted OR 0.41, 95% CI 0.33–0.51, p<0.001). This 
unadjusted mortality difference reduced markedly, but remained statistically significant, 
even after risk adjustment for demographics, hospital characteristics and baseline 
comorbidities (adjusted OR 0.66, 95% CI 0.51 to 0.85, p=0.001). (Table 2) 
Discussion 
 In this largest nationalized “real-world” study of PAH patients to-date, a 
coexisting discharge diagnosis of obesity (present in 14.7% of the PAH patient cohort) 
was associated with lower in-hospital mortality even after extensive adjustment for 
patient demographics, hospitalization characteristics and clinical comorbidities. 
 Obesity has been shown to adversely impact the right ventricular end-diastolic 
pressures, mean pulmonary artery pressures and pulmonary vascular resistance as well as 
CV structure and function.14-17 Thus, survival would be expected to be lower in obese 
PAH patients, the opposite of what we found in our analysis, suggestive of "obesity 
paradox" in PAH. While studies have reported the impact of obesity on pulmonary 
hemodynamics and development of PAH, until now, scant literature existed with respect 
to mortality. Zafrir et al. reported significantly improved survival in obese pulmonary 
hypertension patients during a follow up duration of 19+ 13 months (Hazard ratio (HR) 
0.2, 95% C.I 0.1 to 0.6; p=0.004).9 Similarly, in another study based on subcutaneous 
trepostinil database, a 10 kg/m2 increase in body mass index was reported to significantly 
decrease 10-year mortality (HR 0.68, 95% CI  0.52 to 0.89, p=0.005).8 Poms et al. found 
significantly higher survival in obese PAH patients during long-term follow up in 2,959 
PAH patients from Registry to Evaluate Early And Long-term PAH Disease Management 
registry (HR-0.73, 95% CI 0.61 to 0.86, p <0.001).7 In a recent animal model-based 
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study, the association of obesity and enhanced sympathetic adrenergic state was recently 
hypothesized as a potential explanation for the obesity paradox in PAH.18 To the best of 
our knowledge, our study is the first study to report the protective effect of obesity on in-
hospital mortality in PAH patients at a large, nationwide level. 
 Multiple clinical studies have reported the protective effect of obesity on 
mortality in other CV and pulmonary diseases.3,6,19 Although no clear explanations exist 
for this phenomenon, improved prognosis in obese patients when compared with non-
obese has been related to the excess adipose tissue and higher circulating lipoproteins.20 
Given patients with chronic diseases, such as heart failure, coronary heart disease, and 
chronic obstructive pulmonary disease have higher baseline inflammatory state, with 
markers such as interleukin-1, interleukin-6, tumor necrosis factor –alpha levels, they live 
with higher catabolic burden and cachexia. Similar to the above mentioned chronic 
diseases, PAH has also been reported to have higher levels of tumor necrosis factor-alpha 
and interleukins.21 Hence, as hypothesized in other diseases, the extra adipose reserve 
might potentially provide a buffer for these cytokines in PAH too, thereby, positively 
influencing the prognosis. Other investigators have suggested that obese patients in 
diseases such as heart failure might present earlier in their disease course due to factors 
such as poorer functional status and reduced expression of circulating natriuretic 
peptides, which can lead to medical care and initiation of follow up at a younger age. 22,23 
Additionally, given renin-angiotensin system upregulation in recent experimental PAH 
studies has been strongly related to mortality, obese patients might have an advantage as 
they have attenuated response to renin-angiotensin system. 23 It is critically important to 
emphasize that this strong paradoxical association of obesity with favorable survival does 
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not assume causation and should not be seen as encouragement for weight gain. Clearly 
extensive literature supports that obesity is an established risk factor for the epidemiology 
of CV diseases, as well as its morbidity and mortality.24 However, the existence of 
obesity paradox should stimulate research to elucidate the mechanism(s) behind this 
interesting observation and use it for potentially improving patient care and prognosis. 
 This study has several limitations. Obesity and PAH were identified based on 
ICD-9 codes and information on clinical variables, body mass index, laboratory values, 
hemodynamics and pulmonary vasoactive medications was not available. Hence 
addressing specific issues, such as differences in the prescription and clinical impact of 
medications between two groups is not possible. Also there is a risk that pulmonary 
hypertension secondary to left heart disease or lung disease might have been 
misclassified as PAH, given dependency on ICD-9 codes. The prevalence of obesity in 
our study was lower (15.7%) in comparison to those reported by earlier studies (33-
48%).25,26 Others using Behavioral Risk Factor Surveillance System direct survey have 
previously shown that obesity is underreported in NIS.27 NIS is prone to coding errors; 
is limited to all cause in-patient mortality and the primary discharge diagnosis may not 
reliably represent the condition responsible for hospital admission. Also the possibility 
of residual measured or unmeasured confounding should be noted. Nonetheless, the NIS 
database provided a large nationalized sample of the “real-world” data and high 
statistical power to study the impact of obesity on in-hospital mortality in PAH patients. 
Finally, we do not have data on physical activity, exercise, or fitness, which impacts 
many patients with CV diseases, including potentially those with PH.5,20,28-30 
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Table 1. Pulmonary Arterial Hypertension Patients Baseline Demographics, Hospital 
Characteristics, and Comorbidities  
Variable Overall Obesity p-value  
NO YES 
 n=18,450 n=15,735 n=2,715  
Age, mean ± SD (years) 55.4± 17.5 55.8 ±17.9 53.1±14.8  <0.001 
Women 76.8% 75.6% 83.9% <0.001 
White 65.7% 66.0% 64.0%  
Black 17.2% 16.5% 20.7%  
Hispanic 9.8% 9.9% 9.3%  
Asian or Pacific Islander 2.3% 2.4% 1.5%  
Native American 1.3% 1.3% 1.3%  
Other 3.7% 3.8% 3.1%  
Payer status     
Primary expected payer    <0.001 
Medicare 45.4% 46.6% 38.8%  
Medicaid 16.4% 15.9% 19.0%  
Private insurance 32.1% 31.8% 33.8%  
Self-pay 3.5% 3.2% 5.0%  
No charge 0.4% 0.3% 0.7%  
Other 2.2% 2.1% 2.7%  
Median household income    <0.001 
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0 to 25th  25.6% 25.4% 27.1%  
26th to 50th  25.6% 25.2% 27.7%  
51st to 75th  25.8% 25.7% 26.3%  
76th to 100th  23.0% 23.7% 18.8%  
Admission characteristics     
US Region    <0.001 
Northeast 23.8% 24.3% 20.8%  
Midwest 19.6% 19.6% 19.8%  
South 31.9% 32.2% 30.2%  
West 24.7% 23.9% 29.2%  
Bed size    0.68 
Small 7.3% 7.3% 7.6%  
Medium 18.0% 18.0% 18.4%  
Large 74.7% 74.8% 74.0%  
Urban location 92.5% 92.5% 92.7% 0.68 
Teaching Hospital 68.9% 69.9% 63.2% <0.001 
Elective admission 20.3% 20.7% 18.5% 0.01 
Weekend admission 14.3% 14.1% 15.6% 0.04 
Comorbidities     
Smoking 17.8% 17.4% 20.3% <0.001 
Diabetes mellitus 
(uncomplicated) 
18.8% 16.4% 32.6% <0.001 
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Diabetes mellitus 
(complicated) 
4.3% 3.4% 9.1% <0.001 
Hypertension 36.3% 33.9% 49.9% <0.001 
Dyslipidemia 15.5% 14.4% 21.8% <0.001 
Alcohol abuse 2.3% 2.4% 1.4% <0.001 
Prior myocardial infarction 2.9% 2.8% 2.9% 0.84 
Atrial fibrillation 15.5% 16.1% 12.1% <0.001 
Congestive heart failure 36.0% 35.7% 38.1% 0.01 
Chronic Pulmonary Disease 30.1% 28.9% 36.9% <0.001 
Obstructive Sleep Apnea 10.1% 6.4% 31.4% <0.001 
Peripheral vascular disease 3.4% 3.2% 4.4% <0.01 
Renal Failure 12.6% 12.3% 14.6% 0.001 
Valvular heart disease 14.4% 14.9% 11.8% <0.001 
Acquired immune deficiency 
syndrome 
0.7% 0.8% 0.7% 0.60 
Deficiency anemia 16.6% 16.0% 20.6% <0.001 
Rheumatoid arthritis/collagen 
vascular diseases 
8.1% 8.7% 4.8% <0.001 
Chronic blood loss anemia 0.8% 0.7% 1.2% 0.01 
Coagulopathy 10.0% 10.5% 7.5% <0.001 
Depression 9.8% 9.3% 12.6% <0.001 
Drug abuse 2.7% 2.8% 2.4% 0.29 
Hypothyroidism 14.1% 13.5% 17.5% <0.001 
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Liver disease 7.0% 7.3% 5.4% <0.001 
Lymphoma 1.0% 1.1% 0.8% 0.14 
Fluid and electrolyte disorder 26.0% 26.0% 25.7% 0.78 
Metastatic cancer 0.5% 0.5% 0.0% <0.001 
Other neurologic disorders 4.6% 4.7% 3.9% 0.06 
Paralysis 0.9% 0.9% 0.6% 0.07 
Psychoses 2.7% 2.2% 5.3% <0.001 
Solid tumor without metastasis 0.8% 0.9% 0.6% 0.08 
Weight loss 2.5% 2.6% 1.4% <0.001 
SD, standard deviation 
*Co-morbidities were extracted using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) and Clinical Classifications Software (CCS) 
Codes.11 
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Table 2. Pulmonary Arterial Hypertension patient’s in-hospital mortality, mean length of 
stay and average cost of hospitalization. 
In-Hospital 
Outcomes 
Overall Non-Obese Obese p-value 
Number of cases 
(weighted) 
18,450 15,735 2,715  
In-hospital Mortality  7.4% 8.1% 3.5%  
Unadjusted OR (95% 
CI) 
— Reference 0.41  
(0.33 to 0.51) 
<0.001@ 
Adjusted OR* (95% 
CI) 
— Reference 0.66  
(0.51 to 0.85) 
0.001# 
Median Length of 
Stay (days) 
5(3,8) 5(2,8) 5(3,10) <0.001$ 
Median cost of 
hospitalization (US$) 
25121(13550, 
49733) 
      24226 
(12886,47946) 
28991 
(17413,61001)  
<0.001* 
OR, odds ratio; CI, confidence interval 
*-adjusted for patient demographics, hospital characteristics and clinical comorbidities. 
@
- p value calculated using chi-square test. 
#
- p value calculated using multivariate logistic regression. 
$
- p value calculated using Mann Whitney U test. 
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